Solid Biosciences Inc.
▲ 1 upgrades / ▼ 0 downgrades / 0 reiterations from 1 firms
Nov 2, 2026 (7 days)
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Oct 15, 2026 | UBS | initiate | — → Buy | — | 54% |
| Sep 16, 2026 | RBC Capital | initiate | — → Outperform | — | 55% |
| Sep 14, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| Aug 27, 2026 | Cantor Fitzgerald | maintain | Overweight → Overweight | — | 50% |
| Aug 21, 2026 | Truist Securities | maintain | Buy → Buy | — | 54% |
| Jun 3, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | — | 44% |
| May 18, 2026 | Wedbush | reiterate | Outperform → Outperform | — | 58% |
| May 13, 2026 | Wedbush | maintain | Outperform → Outperform | — | 58% |
| May 13, 2026 | Piper Sandler | maintain | Overweight → Overweight | — | 54% |
| Mar 25, 2026 | JP Morgan | maintain | Overweight → Overweight | — | 54% |
| Mar 23, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| Mar 20, 2026 | Guggenheim | initiate | — → Buy | — | 52% |
| Mar 20, 2026 | Chardan Capital | maintain | Buy → Buy | — | 47% |
| Mar 20, 2026 | Needham | reiterate | Buy → Buy | — | 50% |
| Mar 12, 2026 | Wedbush | maintain | Outperform → Outperform | — | 58% |
| Mar 12, 2026 | Chardan Capital | maintain | Buy → Buy | — | 47% |
| Mar 11, 2026 | Wedbush | reiterate | Outperform → Outperform | — | 58% |
| Feb 9, 2026 | Needham | reiterate | Buy → Buy | $16 | 50% |
| Jan 14, 2026 | Needham | reiterate | Buy → Buy | $16 | 50% |
| Dec 4, 2025 | Needham | initiate | — → Buy | $16 | 50% |
| Nov 5, 2025 | Citigroup | maintain | Buy → Buy | $14 | 54% |
| Nov 5, 2025 | JP Morgan | maintain | Overweight → Overweight | $11 | 54% |
| Nov 4, 2025 | Barclays | maintain | Overweight → Overweight | $9 | 53% |
| Nov 4, 2025 | Chardan Capital | maintain | Buy → Buy | $15 | 47% |
| Aug 14, 2025 | Chardan Capital | maintain | Buy → Buy | $15 | 47% |
| Aug 14, 2025 | JP Morgan | maintain | Overweight → Overweight | $13 | 54% |
| Aug 13, 2025 | Wedbush | maintain | Outperform → Outperform | $14 | 58% |
| Jun 26, 2025 | Citigroup | initiate | — → Buy | $14 | 54% |
| Jun 17, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $20 | 44% |
| Jun 6, 2025 | JMP Securities | reiterate | Market Outperform → Market Outperform | $15 | 53% |
| May 19, 2025 | Chardan Capital | maintain | Buy → Buy | $15 | 47% |
| May 16, 2025 | Piper Sandler | maintain | Overweight → Overweight | $17 | 54% |
| May 16, 2025 | Wedbush | maintain | Outperform → Outperform | $17 | 58% |
| May 16, 2025 | Barclays | maintain | Overweight → Overweight | $10 | 53% |
| Mar 13, 2025 | JP Morgan | maintain | Overweight → Overweight | $11 | 54% |
| Mar 10, 2025 | HC Wainwright & Co. | maintain | Buy → Buy | $20 | 44% |
| Mar 7, 2025 | Chardan Capital | maintain | Buy → Buy | $16 | 47% |
| Mar 7, 2025 | Citizens Capital Markets | reiterate | Market Outperform → Market Outperform | $15 | 49% |
| Feb 19, 2025 | Chardan Capital | maintain | Buy → Buy | $16 | 47% |
| Jan 13, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $16 | 44% |
| Jan 10, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $16 | 44% |
| Jan 8, 2025 | Truist Securities | initiate | — → Buy | $16 | 54% |
| Dec 13, 2024 | Wedbush | initiate | — → Outperform | $16 | 58% |
| Dec 12, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $16 | 44% |
| Dec 10, 2024 | JMP Securities | initiate | — → Market Outperform | $15 | 53% |
| Nov 12, 2024 | JP Morgan | maintain | Overweight → Overweight | $12 | 54% |
| Nov 11, 2024 | Chardan Capital | maintain | Buy → Buy | $15 | 47% |
| Nov 7, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $16 | 44% |
| Aug 14, 2024 | Barclays | maintain | Overweight → Overweight | $15 | 53% |
| Aug 14, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $16 | 44% |
No cross-platform signals in the last 90 days